IBC Life Sciences

Over $3 billion worth of deals regarding siRNA (small interfering RNA) have been forged in the last three years alone. Merck's recent purchase of Sirna Therapeutics is one example showing that big pharma has confidence that therapeutic siRNA can be harnessed to open a new frontier for drug development. Hear Merck's perspective on the utility of RNA therapeutics, including opportunities for vendors and external parties in the RNA synthesis, delivery, and pre-clinical space-and why the potential is so great.

Alan Sachs, Vice President, RNA Therapeutics, Merck Research Laboratories (MRL), assumed leadership of Sirna Therapeutics and established the global MRL RNA Therapeutics Department in January 2007. Prior to this, Dr. Sachs assumed responsibility for the scientific leadership at Rosetta Inpharmatics LLC effective July 2002, responsibility for the Rosetta site effective March, 2004, and overall responsibility for the Department of Molecular Profiling in 2006. Dr. Sachs joined Merck & Co., Inc. as Director of Clinical Genomics for MRL in July 2001.

» Get more information on TIDES® 2008.